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Most breast cancer metastases in bone form osteolytic lesions, but
the mechanisms of tumor-induced bone resorption and destruc-
tion are not fully understood. Although it is well recognized that
Wnt/b-catenin signaling is important for breast cancer tumorigen-
esis, the role of this pathway in breast cancer bone metastasis is
unclear. Dickkopf1 (Dkk1) is a secreted Wnt/b-catenin antagonist.
In the present study, we demonstrated that activation of Wnt/b-
catenin signaling enhanced Dkk1 expression in breast cancer cells
and that Dkk1 overexpression is a frequent event in breast cancer.
We also found that human breast cancer cell lines that preferen-
tially form osteolytic bone metastases exhibited increased levels of
Wnt/b-catenin signaling and Dkk1 expression. Moreover, we
showed that breast cancer cell-produced Dkk1 blocked Wnt3A-
induced osteoblastic differentiation and osteoprotegerin (OPG)
expression of osteoblast precursor C2C12 cells and that these
effects could be neutralized by a specific anti-Dkk1 antibody. In
addition, we found that breast cancer cell conditioned media were
able to block Wnt3A-induced NF-kappaB ligand reduction in
C2C12 cells. Finally, we demonstrated that conditioned media
from breast cancer cells in which Dkk1 expression had been
silenced via RNAi were unable to block Wnt3A-induced C2C12
osteoblastic differentiation and OPG expression. Taken together,
these results suggest that breast cancer-produced Dkk1 may be an
important mechanistic link between primary breast tumors and
secondary osteolytic bone metastases.
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Bone is an active tissue that is maintained by a balance of cellu-
lar activities carried out by specialized cell types. The osteoblasts
are responsible for bone formation. Osteoblasts synthesize and
secrete most proteins of the bone extracellular matrix (ECM) and
express proteins that are both necessary and sufficient to induce
mineralization of this specialized ECM. The osteoclasts are multi-
nucleated cells responsible for bone resorption. Importantly, the
differentiation of osteoclasts is regulated by osteoblasts.1 The re-
ceptor activator of NF-kappaB ligand (RANKL) is expressed by
osteoblastic cells and promotes osteoclast differentiation and ac-
tivity through interaction with its cognate signaling receptor
RANK on the cell surface of hematopoietic cells.2,3 This process
is regulated by osteoprotegerin (OPG), a secreted decoy receptor
of RANKL that binds to and inhibits the activity of RANKL. The
important roles that RANKL, RANK and OPG play in the control
of osteoclast formation have been firmly established.4
The Wnt/b-catenin signaling pathway is involved in various dif-
ferentiation events during embryonic development and, when
aberrantly activated, can lead to tumor formation.5–9 In recent
years, Wnt/b-catenin signaling has been shown to play a substan-
tial role in the control of bone mass and is involved in many disor-
ders of bone.9 Modulation of Wnt/b-catenin signaling in mesen-
chymal progenitors and osteoblasts has revealed that this pathway
controls osteoblast differentiation and is critical for bone homeo-
stasis during postnatal development.10–14 The Wnt target gene
OPG is of particular interest in bone metabolism, as OPG expres-
sion was found to be upregulated by Wnt/b-catenin signaling in
an in vitro screen for Wnt-regulated genes in a multipotent mesen-
chymal cell line.15 Moreover, cellular and molecular studies dem-
onstrated that OPG is a direct target gene of the b-catenin-TCF
complex in osteoblasts.13
Bone metastasis is a frequent complication of cancer.16–18 In
the case of breast cancer, up to 70% of patients with advanced dis-
ease develop osteolytic bone metastases, which are a common
cause of morbidity and sometimes mortality. Recent studies from
multiple myeloma and prostate cancer have implicated an impor-
tant role of Wnt/b-catenin signaling in bone metastasis from these
cancers.19–27 It has been reported that myeloma cells express the
Wnt/b-catenin signaling antagonist Dickkopf1 (Dkk1) and that the
presence of high levels of Dkk1 correlates with focal bone lesions
in patients with myeloma.19 For prostate cancer, it has been dem-
onstrated that tumor cell-produced Wnts act in a paracrine fashion
to induce osteoblastic activity in prostate cancer bone metasta-
sis.20 Although it is well recognized that Wnt/b-catenin signaling
is important for breast cancer tumorigenesis,28–39 the role of this
pathway in breast cancer bone metastasis has never been studied.
In this report, we studied the expression of Dkk1 in human breast
cancer tissues and cultured breast cancer cells and examined the
roles of breast cancer-produced Dkk1 in osteoblastic differentia-
tion and OPG expression. Our data suggest that Dkk1 may be a
critical contributor to the process of breast cancer osteolytic bone
metastasis.
Material and methods
Cell culture and conditioned media
MCF-7 cells, C2C12 cells, Wnt3A-secreting L cells and control
L cells were obtained from American Type Culture Collection.
MDA-MB-231/bone and the parent MDA-MB-231 cells have
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been described before.40 Wnt3A-secreting L cells and control L
cells were cultured in Dulbecco’s minimum essential medium
containing 10% fetal bovine serum, 2 mM L-glutamine, 100 units/
ml penicillin, 100 lg/ml streptomycin and 350 lg/ml G418 and
maintained at 37C in humidified air containing 5% CO2. MCF-7
cells, MDA-MB-231 cells, MDA-MB-231/bone cells and L cells
were cultured in Dulbecco’s minimum essential medium supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/
ml penicillin, and 100 lg/ml streptomycin. Wnt3A-conditioned
medium (CM) and L cell control CM were prepared according to
manufacturer’s specifications. For breast cancer cell CM, MCF-7
cells, MDA-MB-231 cells or MDA-MB-231/bone cells were cul-
tured in 15-cm dishes. After the cells reached confluence, the
media were changed to fresh Dulbecco’s minimum essential me-
dium containing 10% fetal bovine serum for 24 hr. After further
48 hr incubation, the media were collected, centrifuged to remove
cell debris, and stored at280C.
Knockdown of Dkk1 expression
A vector-based short hairpin RNA (shRNA) method was used
to generate MDA-MB-231 cells with inhibited Dkk1 expression.
The preparation of Dkk1 shRNA and control vectors has been
described before.20 Dkk1 shRNA and control were transfected
into human MDA-MB-231 breast cancer cells using FuGENE 6
(Roche) according to manufacturer’s specifications. Individual
clones were selected with 100 lg/ml of Zeocin (Invitrogen). The
Dkk1 levels in cell lysates and cell culture CM were determined
by Western blotting using a specific Dkk1 antibody.
Real-time RT-PCR
TissueScan Breast Cancer Tissue qPCR Array I (BCRT501)
was purchased from Origene. The product contains first-strand
cDNAs prepared from 48 human breast tissues including both ma-
lignant and normal controls. These 48 cDNAs have been normal-
ized against b-actin by RT-PCR, and arrayed onto PCR plates.
Human Dkk1 real-time primer set (PPG01752B) was from Super-
Array. Dkk1 expression was quantitatively measured by real-time
PCR using SYBR Green (Invitrogen) in a total volume of 30 ll
over 42 two-step cycles using the following temperature protocol:
95C for 15 sec and 55C for 60 sec. For analysis of RANKL
expression in C2C12 cells, total RNA was isolated using RNA-
Bee reagent (Tel-Test); first-strand cDNA synthesis was per-
formed using ProSTARTM Ultro HF RT-PCR Kit (Strategene)
primed with oligo(dT) primer in a 10 ll reaction mixture contain-
ing 0.5 lg total RNA, and real-time RT-PCR for RANKL mRNA
was performed as described in Ref. 41
Western blotting
Cells in 6-well plates were lysed in 0.5 ml of lysis buffer (phos-
phate-buffered saline containing 1% Triton X-100 and 1 mM
PMSF) at 4C for 30 min. Equal quantities of protein were sub-
FIGURE 1 – Dkk1 is frequently upregulated in human breast cancer. (a) Breast cancer TissueScan Real-Time qPCR array was analyzed for
Dkk1 expression by real-time PCR. Averages of relative Dkk1 expression from three independent plates are plotted with clinical status indi-
cated. Four samples with extremely high Dkk1 levels are marked with numbers. (b) Breast tumors with relative Dkk1 expression that is lower
(Dkk12) or higher (Dkk11) than 10 in (a) were analyzed against estrogen receptor (ER) and progesterone receptor (PR) status. Note that high
levels of Dkk1 expression are over-represented in ER/PR-double negative breast tumors.
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jected to SDS-PAGE under reducing conditions. Following the
transfer to immobilon-P transfer membrane, successive incuba-
tions with either anti-Dkk1 (R&D Systems), anti-b-catenin (BD
Biosciences), anti-OPG (R&D systems), anti-Axin2 (Cell Signal-
ing) or anti-actin (Sigma) and horseradish peroxidase-conjugated
secondary antibody were carried out for 60–120 min at room tem-
perature. The immunoreactive proteins were then detected using
the ECL system. Films showing immunoreactive bands were
scanned by Kodak Digital Science DC120 Zoom Digital Camera
and analyzed with Kodak Digital Science1D Image Analysis
Software.
GST-E-cadherin binding assay
Plasmid pGST-E-cadherin was provided by Dr. Gail Johnson
(University of Alabama at Birmingham, Alabama). The GST-E-
cadherin binding assay was carried out exactly as previously
described.42–44 Uncomplexed b-catenin present in 100 lg of total
cell lysate was subjected to SDS-PAGE and detected using a
monoclonal antibody to b-catenin.
Alkaline phosphatase activity assay
C2C12 cells in 12-well plates were treated with Wnt3A CM,
breast cancer cell CM, and anti-Dkk1 IgG (R&D Systems), as
described in each figure legend. Cells were harvested 48 hr later
for assay of alkaline phosphatase (ALP) activity (Pierce) by deter-
mining the amount of p-nitrophenol synthesized from p-nitrophe-
nylphosphate according to the manufacturer’s specifications. Cell
lysates were analyzed for protein content using a Bio-Rad protein
assay kit, and ALP activity was normalized to total protein content
in each well.
Cell proliferation assay
Cells were seeded into 96-well tissue culture microtiter plates at
a density of 5,000 cells/well. After 24 hr incubation, cells were
treated with 25% of breast cancer CM for 72 hr. Cell proliferation
was measured by the MTT assay kit (Promega).
Results
Dkk1 is frequently upregulated in human breast malignant tissues
To examine whether Dkk1 overexpression is a frequent event in
human breast cancer, we analyzed Dkk1 expression in breast can-
cer tissues by quantitative real-time RT-PCR, using a Breast Can-
cer TissueScan Real-Time qPCR Arrays (Origene). This array
contains 7 normal control breast tissues and 41 breast cancer tis-
sues representing different clinical stages. All the samples were
from female patients with ages ranging from 31 to 75. Pathologi-
cal information including hormone receptor status is provided for
each sample. As seen in Fig. 1a, we found that Dkk1 expression
was low in all 7 control samples, whereas about 50% of the breast
cancer tissues exhibited high levels of Dkk1. It is interesting to
note that high levels of Dkk1 expression were overrepresented in
estrogen receptor (ER)/progesterone receptor (PR)-double nega-
tive breast tumors (Fig. 1b), suggesting that Dkk1 is preferentially
expressed in hormone-resistant breast tumors, which typically
have poorer prognosis. Together, these results indicate that Dkk1
overexpression is a frequent event in human breast cancer.
Dkk1 is upregulated in human breast bone metastatic cancer cells
Breast cancer MDA-MB-231 cells form typical osteolytic bone
metastases when inoculated into the arterial circulation of
mice.40,45–47 MDA-MB-231/bone is a subpopulation of MDA-
MB-231 that was isolated by in vivo selection.48 MDA-MB-231/
bone cells exclusively metastasize to bone with larger osteolytic
lesions than the parent MDA-MB-231 cells.48 To explore the role
of Dkk1 in breast cancer bone metastases, we examined Dkk1
expression in MDA-MB-231 and MDA-MB-231/bone cells. We
found that MDA-MB-231/bone cells exhibited higher levels of
Dkk1 expression and Dkk1 secretion into the conditioned media
than the parent MDA-MB-231 cells (Fig. 2a). Quantification of
the Western blot signals revealed that the levels of Dkk1 in CM
and total cellular Dkk1 in MDA-MB-231/bone cells were 4.5-fold
and 3.1-fold higher than those in the parent MDA-MB-231 cells,
respectively. MCF-7 is another breast cancer cell line that is com-
monly used for bone metastasis studies. However, MCF-7 cells
display lower metastatic activity and form smaller bone osteolytic
lesions than MDA-MB-231 cells.49–52 Interestingly, we also found
that MCF-7 cells displayed lower levels of Dkk1 expression and
Dkk1 secretion than MDA-MB-231 cells (Fig. 2a). Quantification
of the Western blot signals revealed that the levels of Dkk1 in CM
and total cellular Dkk1 in MDA-MB-231 cells were 3.3-fold and
2.7-fold higher than those in MCF-7 cells, respectively. Together,
our results suggest that breast cancer cells with high levels of met-
astatic activity exhibit high levels of Dkk1 expression and
secretion.
Induction of Dkk1 expression by activation of Wnt/b-catenin
signaling in breast cancer cells
It has been recently demonstrated that Dkk1 is a direct down-
stream target of Wnt/b-catenin signaling in several cell line
models.53–55 Wnt/b-catenin signaling is overactivated in breast
cancer.28–39 At the heart of the Wnt/b-catenin pathway is the sta-
bilization of cytosolic b-catenin, which binds to transcription
FIGURE 2 – Wnt/b-catenin signaling activation and Dkk1 expres-
sion in human breast cancer cells in culture. (a) Wnt/b-catenin signal-
ing in human breast cancer cells. Cytosolic free b-catenin from MCF-
7, MDA-MB-231 and MDA-MB-231/bone cells was pulled down
from 100 lg of cell lysate using pGST-E-Cadherin and then examined
by Western blotting with a specific b-catenin antibody. The levels of
total cellular b-catenin and Axin2 were analyzed by Western blotting
with a specific b-catenin antibody or Axin2 antibody, and the samples
were also probed with an anti-actin antibody to verify equal loading.
(b) Dkk1 expression in human breast cancer cells. The level of total
cellular Dkk1 from MCF-7, MDA-MB-231 and MDA-MB-231/bone
cells were analyzed by Western blotting with a specific Dkk1 anti-
body, and the samples were also probed with an anti-actin antibody to
verify equal loading. Dkk1 in 24-hr serum free conditioned media
(CM) was normalized by protein concentrations and examined by
Western blotting.
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factors of the T-cell factor/lymphoid enhancing factor (TCF/LEF)
family, leading to the transcription of Wnt/b-catenin target genes.
Using the GST-E-cadherin binding assay and subsequent Western
blotting,42–44 we examined cytosolic free b-catenin levels as a mea-
sure of Wnt/b-catenin signaling activation. We found that MDA-
MB-231/bone cells exhibited the highest level of uncomplexed cyto-
solic b-catenin (free b-catenin), while MCF-7 cells displayed the
lowest level of free b-catenin (Fig. 2b). Quantification of the West-
ern blot signals revealed that the levels of free b-catenin in MDA-
MB-231/bone cells were 31-fold and 4.4-fold higher than those in
MCF-7 and MDA-MB-231 cells, respectively.
Axin2 is a specific transcriptional target of the Wnt/b-catenin sig-
naling pathway. It is well recognized that the expression level of
Axin2 is a signature of the activation of the Wnt/b-catenin signaling
pathway.56–59 To further examine the activation of Wnt/b-catenin
signaling in breast cancer cells, we studied Axin2 expression by
Western blotting. As expected, MDA-MB-231/bone cells exhibited
the highest level of Axin2 expression, while MCF-7 cells displayed
the lowest level of Axin2 expression (Fig. 2b). Quantification of the
Western blot signals revealed that the levels of Axin2 in MDA-MB-
231/bone cells were 6.5-fold and 3.2-fold higher than those in MCF-
7 and MDA-MB-231 cells, respectively.
Previous studies have shown that Wnt3A is a canonical Wnt
ligand that binds to the low density lipoprotein receptor-related pro-
teins (LRP) and frizzled receptors, leading to the activation of Wnt/
b-catenin signaling.60 To confirm that Dkk1 expression is upregu-
lated via Wnt/b-catenin signaling in human breast cancer cells, we
treated MDA-MB-231 cells with either L cell Wnt3A CM or control
CM. As shown in Figures 3a and 3b, treatment of MDA-MB-231
cells with Wnt3A CM significantly increased free b-catenin level
and Axin2 expression. Quantification of the Western blot signals of
free b-catenin and Axin2 revealed 18-fold and 3.9-fold increases
when compared with control cells, respectively. Consistent with the
activation of Wnt/b-catenin signaling by Wnt3A, the levels of en-
dogenous Dkk1 in total cellular lysates and those secreted into the
conditioned media were significantly increased (Fig. 3c).
Effects of breast cancer cell CM on C2C12 cell proliferation
C2C12 cells are uncommitted mesenchymal progenitor cells
that can be differentiated into osteoblasts upon activation of Wnt/
b-catenin signaling.19 We employed C2C12 cells to examine the
effects of breast cancer-produced Dkk1 on osteoblast proliferation,
differentiation and function. As shown in Figure 4, breast cancer
cell CM slightly decreased the growth of C2C12 cells at 72 hr
treatment. Furthermore, there was no significant difference of
C2C12 cell proliferation after the cells were treated with different
breast cancer cell conditioned media.
FIGURE 3 – Induction of Dkk1 expression by Wnt3A in MDA-MB-231 cells. (a) Wnt3A stabilized cytosolic free b-catenin in MDA-MB-231
cells. MDA-MB-231 cells in 6 well plates were incubated with 25% of either L cell control CM or Wnt3A CM for 3 hr. The level of total cellu-
lar b-catenin was analyzed by Western blotting, and the samples were also probed with an anti-actin antibody to verify equal loading. Cytosolic
free b-catenin was pulled down from 100 lg of cell lysate using pGST-E-Cadherin and then examined by Western blotting. (b) Wnt3A induced
Axin2 expression in MDA-MB-231 cells. MDA-MB-231 cells in 6 well plates were incubated with 25% of either L cell control CM or Wnt3A
CM for 48 hr. The level of total cellular Axin2 was analyzed by Western blotting. (c) Wnt3A induced Dkk1 expression and secretion in MDA-
MB-231 cells. MDA-MB-231 cells in 6-well plates were incubated with 25% of either L cell control CM or Wnt3A CM. After 36-hr incubation,
the cells were cultured in serum free medium for 8 hr. The level of total cellular Dkk1 was analyzed by Western blotting. Level of Dkk1 in 8-hr
serum free CM was normalized by protein concentrations and then analyzed by Western blotting. Right panel, quantification of the Western blot
signals of Dkk1 in CM and total cellular Dkk1 expression, which was normalized to the actin level, from 3 determinations. **p < 0.01 indicates
a significant difference compared with cells incubated with L cell control CM.
FIGURE 4 – Effects of breast cancer cell CM on C2C12 cell prolifer-
ation. C2C12 cells in 96-well plates were treated with 25% of breast
cancer CM for 72 hr, and cell growth was assessed using the MTT
assay. Values are the average of triple determinations with the stand-
ard deviation indicated by error bars.
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Breast cancer cell-produced Dkk1 blocks Wnt3A-induced
osteoblastic differentiation of C2C12 cells
Wnt3A can induce differentiation of uncommitted mesenchy-
mal progenitor-cells into osteoblasts through the activation of
Wnt/b-catenin signaling.19 Wnt3A are expressed in osteoblasts
and several breast cancer cell lines.14,43 To determine whether
breast cancer cell-produced Dkk1 affects Wnt3A-induced osteo-
blastic differentiation, we examined the activity of alkaline phos-
phatase (ALP), a specific marker of osteoblast differentiation, in
C2C12 cells. It was found that only small amounts of ALP were
detectable in C2C12 cells without Wnt3A stimulation, and that
breast cancer cell CM alone had no effects on basal level of ALP
activity in C2C12 cells (Fig. 5a). On the other hand, treatment of
C2C12 cells with media containing Wnt3A CM for 2 days greatly
induced ALP expression, which was blocked by recombinant
Dkk1 protein (Fig. 5a). Interestingly, conditioned media from
MDA-MB-231 cells or MDA-MB-231/bone cells, but not from
MCF-7 cells, inhibited the Wnt3A-induced ALP production in
C2C12 cells (Fig. 5b). More importantly, this effect on ALP pro-
duction was neutralized by a polyclonal anti-Dkk1 antibody but
not by a nonspecific polyclonal goat IgG (Figs. 5c and 5d).
Breast cancer cell-produced Dkk1 blocks Wnt3A-induced
OPG expression in C2C12 cells
Recent studies have demonstrated that OPG is a direct target
gene of Wnt/b-catenin signaling in osteoblasts and that Wnt/b-
catenin signaling controls bone resorption by directly regulating
RANKL/RANK/OPG signaling activity.10–14 To determine
whether breast cancer cell-produced Dkk1 affects Wnt3A-induced
OPG expression in osteoblasts, we examined OPG expression in
C2C12 cells. It was found that OPG was nearly undetectable in
C2C12 cells without Wnt3A stimulation and that breast cancer
cell CM alone had no significant effect on basal level of OPG
expression in C2C12 cells (Fig. 6a). On the other hand, treatment
of C2C12 cells with Wnt3A CM for 2 days greatly induced OPG
expression, which was completely blocked by recombinant Dkk1
protein (Fig. 6a). As expected, conditioned medium from MDA-
MB-231 cells or MDA-MB-231/bone cells, but not from MCF-7
cells, inhibited Wnt3A-induced OPG expression in C2C12 cells
(Fig. 6b). Quantification of the Western blot signals revealed that
OPG expression was reduced to 25% and 12% after C2C12 cells
were treated with MDA-MB-231 CM and MDA-MB-231 CM,
respectively. Furthermore, this effect on OPG expression was neu-
tralized by a polyclonal anti-Dkk1 antibody but not by a nonspe-
cific polyclonal goat IgG (Fig. 6c).
Breast cancer cell CM blocked Wnt3A-induced RANKL
reduction in C2C12 cells
Recent studies have demonstrated that expression of RANKL,
another key player of the RANK/RANKL/OPG signaling path-
way, is also regulated by Wnt/b-catenin signaling in osteo-
blasts.12,14,41 To determine whether breast cancer cell CM affects
RANKL expression in osteoblasts, we examined RANKL mRNA
by real-time RT-PCR in C2C12 cells. As shown in Fig. 7a, breast
cancer cell CM alone had no significant effect on basal level of
RANKL expression in C2C12 cells. Treatment of C2C12 cells
FIGURE 5 – Breast cancer cell-produced Dkk1 blocks Wnt3A-induced osteoblastic differentiation of C2C12 cells. (a) Dkk1 blocked Wnt3A-
induced ALP in C2C12 cells. C2C12 cells in 12-well plates were incubated breast cancer CM (25%), Wnt3A CM (10%) and Dkk1 (300 ng/ml)
as indicated for 48 hr. ALP activity was measured as described under ‘‘Materials and Methods’’. (b) Conditioned media from breast cancer cells
blocked Wnt3A-induced ALP in C2C12 cells. C2C12 cells in 12-well plates were incubated with Wnt3A CM in the presence or absence breast
cancer CM as indicated. Cells were harvested 48 hr later and assayed for ALP activity. (c–d) Anti-Dkk1 antibody reversed the effect of breast
cancer cell CM on Wnt3A-induced ALP production in C2C12 cells. C2C12 cells in 12-well plates were incubated with Wnt3A CM, breast can-
cer CM and a polyclonal anti-Dkk1 antibody as indicated. Cells were harvested 48 hr later for assay for ALP activity. In (c), MDA-MB-231 CM
was used. In (d), MDA-MB-231/bone CM was used. All the values are the average of triple determinations with the standard deviation indicated
by error bars. *p < 0.05 indicates a significant difference compared with cells incubated with Wnt3A CM along with L cell control CM. **p <
0.01 indicates a significant difference compared with cells incubated with Wnt3A CM along with L cell control CM, or cells incubated with
Wnt3A CM along with breast cancer CM and anti-Dkk1 antibody.
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with Wnt3A CM for 3 days resulted in a significant decrease in
RANKL expression, which was blocked by recombinant Dkk1
protein (Fig. 7a). Importantly, conditioned media from MDA-MB-
231/bone cells were also able to block the Wnt3A-induced
RANKL reduction in C2C12 cells, although conditioned media
from MDA-MB-231 cells only partially blocked the Wnt3A-
induced RANKL reduction (Fig. 7b).
MDA-MB-231 cells with Dkk1 knockdown are unable to
block Wnt3A-induced C2C12 cell osteoblastic
differentiation and OPG expression
To further define the roles of breast cancer-produced Dkk1 in
osteoblast differentiation and OPG expression, we stably
expressed a Dkk1 shRNA20 in MDA-MB-231 cells. Figure 8a
shows that a single MDA-MB-231 clone stably transfected with
FIGURE 6 – Breast cancer cell-produced Dkk1 blocked Wnt3A-induced OPG expression in C2C12 cells. (a) C2C12 cells in 6-well plates were
incubated with breast cancer CM (25%), Wnt3A CM (20%) and Dkk1 (300 ng/ml) as indicated for 48 hr, and OPG expression was examined by
Western blotting. (b) Conditioned media from breast cancer cells block Wnt3A-induced OPG expression in C2C12 cells. C2C12 cells in 6-well
plates were incubated with Wnt3A CM in the presence or absence breast cancer CM as indicated. Cells were harvested 48 hr later for Western
blotting of OPG expression. (c). Anti-Dkk1 antibody reversed the effect of breast cancer cell CM on Wnt3A-induced OPG expression in C2C12
cells. C2C12 cells in 6-well plates were incubated with Wnt3A CM, breast cancer CM and a polyclonal anti-Dkk1 antibody as indicated. Cells
were harvested 48 hr later for Western blotting for OPG with a specific anti-OPG antibody. Right panel, quantification of the Western blot sig-
nals of OPG expression, which was normalized to actin level, from 3 independent experiments. *p < 0.05 indicates a significant difference com-
pared with cells incubated with Wnt3A CM along with L cell control CM, or cells incubated with Wnt3A CM along with breast cancer CM and
anti-Dkk1 antibody.
FIGURE 7 – Breast cancer cell CM blocked Wnt3A-induced RANKL reduction in C2C12 cells. C2C12 cells in 6-well plates were incubated
with breast cancer CM (25%), Wnt3A CM (20%) and Dkk1 (300 ng/ml) as indicated for 72 hr. Cells were harvested and RANKL mRNA was
determined by real-time RT-PCR. All the values are the average of triple determinations with the standard deviation indicated by error bars. *p
< 0.05 indicates a significant difference compared with cells incubated with Wnt3A CM plus Dkk1, or cells without Wnt3A treatment. #p <
0.05 indicates a significant difference compared to cells incubated Wnt3A CM along with L cell control CM.
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Dkk1-shRNA exhibited significant downregulation of the Dkk1
protein in the conditioned media. Quantification of the Western
blot signals revealed that Dkk1 in CM and total cellular Dkk1 in
MDA-MB-231 Dkk1-shRNA cells were reduced to 8% and 17%
than those in control cells, respectively. Moreover, conditioned
media from MDA-MB-231 Dkk1-shRNA cells failed to block
Wnt3A-induced ALP production (Fig. 8b) and OPG expression
(Fig. 8c). Taken together, these results show that reducing the
expression of the Wnt/b-catenin signaling inhibitor Dkk1
unmasked an osteoinductive effect in osteolytic MDA-MB-231
cells.
Discussion
Dkk1 is a secreted protein that negatively modulates the Wnt/b-
catenin pathway. In contrast to other Wnt/b-catenin signaling
antagonists, Dkk1 is overexpressed in many malignant tissues
including breast cancer,61 lung cancer,62 esophageal carcinomas,62
multiple myeloma,19 ovarian endometrioid adenocarcinomas,55
hepatoblastomas and Wilms’ tumors.63 In the case of breast can-
cer, it has been reported that Dkk1 is preferentially expressed in
ER and PR-negative tumors and in tumors from women with a
family history of breast cancer.61 Furthermore, Dkk1 is a potential
prognostic and diagnostic marker for cohorts of breast cancer
patients with poor prognosis.61 In the present study, by using a
Breast Cancer TissueScan Real-Time qPCR array, we also found
that 50% of the breast cancer tissues exhibited high levels of
Dkk1 and that high levels of Dkk1 expression were overrepre-
sented in ER/PR-double negative breast tumors. All together,
these studies suggest that Dkk1 is frequently overexpressed in
breast malignant tissues.
Recent studies have demonstrated that Dkk1 is not only a key
inhibitor but also a direct downstream target of Wnt/b-catenin sig-
naling. Activation of Wnt/b-catenin signaling by Wnt1 or ectopic
expression of active b-catenin, TCF4 or LRP6 mutants induces
transcription of the human Dkk1 gene in several cell line models
in vitro.53–55 Multiple b-catenin/TCF4 binding sites in the Dkk1
gene promoter region allow for this activation.53–55 In the present
study, we demonstrate that Wnt3A activates Wnt/b-catenin signal-
ing and enhances Dkk1 expression in breast cancer MDA-MB-231
cells. Although genetic mutations of APC or b-catenin are rarely
observed in breast cancer, compelling evidence has implicated
abnormal regulation of Wnt/b-catenin signaling in tumorigenic
FIGURE 8 – MDA-MB-231 cells with Dkk1 knockdown were unable to block Wnt3A-induced osteoblastic differentiation and OPG expres-
sion. (a) Reduction of Dkk1 protein expression in MDA-MB-231 cells by shRNA. MDA-MB-231 cells stably transfected with Dkk1-shRNA
expression vector or control shRNA vector were cultured in 6-well plates. Cell lysates and 24-hr serum free CM were prepared. The level of total
cellular Dkk1 was analyzed by Western blotting, and the samples were also probed with an anti-actin antibody to verify equal loading. Level of
Dkk1 in 24-hr serum free CM was normalized by protein concentrations, and then analyzed by Western blotting. (b) MDA-MB-231 cells with
Dkk1 knockdown were unable to block Wnt3A-induced C2C12 cell osteoblastic differentiation. C2C12 cells in 12-well plates were incubated
with Wnt3A CM in the presence or absence breast cancer CM as indicated. Cells were harvested 48 hr later for assay for ALP activity. Values
are the average of triple determinations with the standard deviation indicated by error bars. *p < 0.01 indicates a significant difference compared
with cells incubated with Wnt3A CM along with L cell control CM, or cells incubated with Wnt3A CM along with CM from breast cancer
MDA-MB-231 Dkk1-shRNA. (c) MDA-MB-231 cells with Dkk1 knockdown were unable to block Wnt3A-induced OPG expression in C2C12
cells. C2C12 cells in 6-well plates were incubated with Wnt3A CM in the presence or absence breast cancer CM as indicated. Cells were har-
vested 48 hr later for Western blotting for OPG with a specific anti-OPG antibody. Right panel, quantification of the Western blot signals of
OPG expression, which was normalized to the actin level, from 3 independent experiments. *p < 0.05 indicates a significant difference com-
pared with cells incubated to Wnt3A CM along with L cell control CM, or cells incubated with Wnt3A CM along with breast cancer CM and
anti-Dkk1 antibody.
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program of breast cancer. For example, Wnt1, the founding mem-
ber of the Wnt gene family, was initially identified as a mammary
oncogene insertionally activated by mouse mammary tumor
virus.28–30 Overexpression of several Wnts has been reported in
breast cancer.31–33,39 Secreted Frizzled-related protein1 (sFRP1), a
member of the secreted Wnt antagonist family, is downregulated
in breast cancers.34 Upregulation of b-catenin mRNA levels was
detected by microarray analysis in human breast cancer.35 More
importantly, it has been reported that b-catenin protein levels are
significantly upregulated in human breast cancer tissues and corre-
late with poor prognosis, acting as a strong and independent prog-
nostic factor in human breast cancer patients.36–38 Thus, Dkk1
upregulation is likely a consequence of overactivation of Wnt/b-
catenin signaling in human breast cancer. Further studies will be
required to define whether Dkk1 expression is correlated with the
activation of Wnt/b-catenin signaling in human breast cancer tis-
sues. As Dkk1 is a major antagonist of Wnt/b-catenin signaling, it
will be also interesting to explore the mechanism employed by
human breast cancer cells that are able to escape Dkk1 inhibition.
Studies in the past several years have established that Wnt/b-
catenin signaling plays a critical role in the regulation of bone
mass and is a causative factor for many disorders of the bone.
Osteoblast differentiation is the primary event of bone formation,
characterized by the synthesis, deposition and mineralization of
the extracellular matrix. One of the mechanisms whereby Wnt/b-
catenin signaling increases bone formation is via stimulation of
the development of osteoblasts.9 In the present study, we demon-
strate that human breast cancer cells with a predisposition toward
the formation of osteolytic bone metastases exhibit increased lev-
els of Dkk1 expression and that breast cancer cell-produced Dkk1
inhibits the Wnt3A-induced osteoblastic differentiation of osteo-
blast precursor C2C12 cells. These results suggest that breast can-
cer-produced Dkk1 is involved in breast cancer-derived osteolytic
metastases.
It has been demonstrated that Wnt/b-catenin signaling in osteo-
blasts is able to coordinate postnatal bone acquisition by control-
ling the differentiation and activity of osteoclasts. OPG is a direct
target gene of the b-catenin-TCF complex in osteoblasts13,15 and
acts as a decoy receptor that blocks the binding of RANKL to its
cognate signaling receptor RANK on hematopoietic cells, thereby
inhibiting osteoclast formation and activity.2–4 In the present study,
we found that breast cancer cell-produced Dkk1 inhibited Wnt3A-
induced OPG expression and RANKL reduction in osteoblast pre-
cursor C2C12 cells, strengthening the notion that breast cancer-
produced Dkk1 could be a critical modulator for breast cancer
osteolytic metastases. In the future, we should examine whether
Dkk1 is frequently upregulated in human breast cancer patient
serums and malignant tissues with osteolytic bone metastases.
In summary, we propose that Dkk1 expression in breast cancer
cells contributes to the development and progression of breast
osteolytic bone metastases. Breast cancer cells with overactivated
Wnt/b-catenin signaling produce high levels of Dkk1, which
blocks osteoblast differentiation, OPG expression and RANKL
reduction, and, consequently, stimulates osteoclastic bone resorp-
tion. Thus, Dkk1 is a potential therapeutic target in designing
pharmacologic interventions for bone metastases in breast cancer.
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